Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
COVID-19
COVID-19 Daily Update
COVID-19 EventAnalyzer
COVID-19 Stories from Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
EvaluatePharma Vision
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Custom Solutions
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial team
About Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
English
日本語
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Speedel
September 18, 2013
On a wing and a prayer, Clovis calls the top
March 16, 2010
Novartis pushes on with efforts to protect hypertension franchise
February 06, 2009
Novartis on the acquisition trail?
January 26, 2009
Small is beautiful for Glaxo
July 10, 2008
Cytos climbs on allergy data and takeout fantasies
July 10, 2008
Tekturna turns into nice little earner
June 18, 2008
Novartis trials could be distant turning point for Tekturna
April 28, 2008
R&D productivity - focus on quality not just quantity
April 03, 2008
Not quite time to write off Tekturna
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 20, 2020
Vantage Pharma, Biotech & Medtech 2019 in Review
December 17, 2019
Vantage 2020 Preview
Editor's Picks
March 18, 2020
A Covid-19 treatment plan slowly emerges
March 11, 2020
Tiziana takes a deep breath and targets Covid-19
March 12, 2020
Estimating the cost of Covid-19 antiviral development
March 10, 2020
Few groups have developed Covid-19 diagnostics – but this will change
March 20, 2020
Clinical trial delays become reality as Covid-19 risk spreads
